Here, we use a pyridinecarbaldehyde rhodamine 6G hydrazone ligand (L) to synthesize an Fe(II) complex 1 for the search of new fluorescent-spin crossover (SCO) materials. Single-crystal structural determinations suggest that the Fe(II) ion is chelated by two ring-opened ligands (L-o) to form a FeNO coordination environment, and intermolecular π---π contacts of the xanthene groups connect the adjacent molecules to form a supramolecular one-dimensional chain. Magnetic susceptibility measurements on complex 1 show that three-step SCO takes place in the temperature range of 120-350 K, and its desolvated form 1-d exhibits SCO around room temperature ( T↑ = 343 K and T↓ = 303 K) with a wide hysteresis loop of 40 K. Moreover, complex 1-d displays light-induced excited spin-state trapping phenomenon. Intriguingly, the fluorescence intensity of the maximum emission at 560 nm for complex 1-d displays discontinuous variation in the range of 250-400 K, indicative of the occurrence of synergetic fluorescence and SCO.

Solubility data of carbon dioxide (CO 2 ) (1) in propanone (2), 1-ethyl-3-methylimidazolium ([EMIM] + [BF4] -) (3), and their mixtures (w 3 ) 0.10, 0.20, and 0.50) at temperatures (298.2 and 313.2) K and pressures up to 8.0 MPa were measured by means of a high-pressure view-cell technique. Henry's law was applied to correlate the experimental data, and it was found that the magnitude of Henry's constants for propanone (w 3 ) 0.0), [EMIM] + [BF4] -(w 3 ) 1.0), and their mixtures follows the order of w 3 ) 0.0 < w 3 ) 0.10 < w 3 ) 0.20 < w 3 ) 0.50 < w 3 ) 1.0 at a given temperature. The mixtures of propanone and [EMIM] + [BF4]may be used as promising solvents for capturing CO 2 since they combine the advantages of organic solvents and ionic liquids.

A wait-and-see policy might be considered instead of surgery for rectal cancer patients with no residual tumor or involved lymph nodes on imaging or endoscopy after neoadjuvant chemoradiotherapy (clinical complete response, cCR). In this cohort study, we compared the oncologic outcomes of rectal cancer patients with a cCR who were managed according to a wait-and-see policy (observation group) or with surgery (surgery group). In the observation group, follow-up was performed every 3 months for the first year and consisted of MRI, endoscopy with biopsy, computed tomography and transrectal ultrasonography. In the surgery group, patients received radical surgery. Long-term oncologic outcomes were estimated using Kaplan-Meier curves. Thirty patients were enrolled in the observation group (median follow-up, 60 months; range, 18-100 months), and 92 patients were enrolled in the surgery group (median follow-up, 58 months; range, 18-109 months). The 5-year disease free survival and overall survival rates were similar in the two groups: 90.0% vs. 94.3% (P = 0.932) and 100.0% vs. 95.6% (P = 0.912), respectively. We conclude that for rectal cancer patients with a cCR after neoadjuvant chemoradiotherapy, a wait-and-see policy with strict selection criteria, follow-up and salvage treatments achieves outcomes at least as good as radical surgery. Additionally, we declare that the pCR (pathologic complete regression) and non-pCR subgroups of patients with a cCR have similar long-term failure (local recurrence and/or distant metastasis) rate.

Wait-and-see treatment strategies may benefit rectal cancer patients who achieve a clinical complete response (cCR) after neoadjuvant chemoradiotherapy (NCRT). In this study, we analyzed data from 9 eligible trials to compare the oncologic outcomes of 251 rectal cancer patients achieving a cCR through nonsurgical management approaches with the outcomes of 344 patients achieving a pathologic complete response (pCR) through radical surgery. The two patient groups did not differ in distant metastasis rates or disease-free and overall survival, but the nonsurgical group had a higher risk of 1, 2, 3, and 5-year local recurrence. Hence, we concluded that for rectal cancer patients achieving a cCR after NCRT, a wait-and-see strategy with strict selection criteria, an appropriate follow-up schedule, and salvage treatments achieved outcomes at least as good as radical surgery. Long-term randomized and controlled trials with more uniform inclusion criteria and standardized follow-up schedules will help clarify the risks and benefits of wait-and-see treatment strategies for these patients.

No abstract